Based on these findings, different Eg5 inhibitors were synthesized and tested in in vitro cancer models, and the most promising have entered clinical trials [23,24,25,26], such as the dihydropyrimidine scaffold-based [27,28], quinazolinones [26], chromen-4-ones [29], benzimidazoles [30], and thiadiazolines [31]. This evidence concerns the gene KIF11 and cancer.